{"product_id":"amgen-business-model-canvas","title":"Amgen Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmgen's Business Model: A Deep Dive\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover the intricate framework that powers Amgen's success. This comprehensive Business Model Canvas breaks down their customer relationships, revenue streams, and key resources, offering a clear view of their operational genius. For anyone aiming to replicate or innovate within the biotech sector, this is an indispensable resource.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen actively partners with premier academic and research institutions worldwide, including renowned entities like MIT, Harvard Medical School, and Stanford University. These collaborations are vital for advancing early-stage research, fostering scientific breakthroughs, and tapping into pioneering technologies and specialized knowledge, thereby nurturing Amgen's innovation pipeline.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Amgen demonstrated a significant commitment to innovation through its substantial R\u0026amp;D investment, which totaled $5.1 billion. This financial outlay underscores the company's reliance on external academic and research partnerships to drive its scientific endeavors and maintain a competitive edge in the biopharmaceutical industry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Licensing and Acquisition Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen leverages pharmaceutical licensing and acquisition agreements as a core component of its strategy to broaden its therapeutic pipeline and geographic reach. This approach allows for rapid access to innovative science and established products.\u003c\/p\u003e\n\u003cp\u003eA prime example of this strategy in action was Amgen's acquisition of Horizon Therapeutics plc, which closed in October 2023 for approximately $27.8 billion. This significant transaction bolstered Amgen's presence in rare diseases and immunology, adding key medicines like Tepezza and Krystexxa to its portfolio.\u003c\/p\u003e\n\u003cp\u003eFurthermore, Amgen engages in strategic collaborations to advance specific therapeutic areas. For instance, its partnership with BeiGene, Ltd., established in 2023, focuses on developing and commercializing oncology treatments in China and other Asian markets, aiming to capitalize on the region's growing healthcare needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations (CMOs)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen leverages Contract Manufacturing Organizations (CMOs) to enhance its supply chain and fulfill worldwide demand for its biopharmaceutical products. These collaborations are crucial for managing production capacity and ensuring consistent therapy availability across the globe.\u003c\/p\u003e\n\u003cp\u003eThese partnerships allow Amgen to scale production efficiently, complementing its internal manufacturing capabilities. For instance, Amgen announced a significant $1 billion expansion of its manufacturing facility in North Carolina, which began in 2024, demonstrating a commitment to bolstering its own production capacity alongside external partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Technology and AI Firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen actively cultivates strategic alliances with leading medical technology companies.  These collaborations are crucial for accessing cutting-edge tools and expertise, particularly in areas like genomic sequencing.  For example, Amgen partners with Illumina, a prominent player in this field, to enhance its research capabilities.\u003c\/p\u003e\n\u003cp\u003eThe company is also significantly expanding its use of artificial intelligence (AI) through key partnerships. A notable instance is the November 2023 announcement of Amgen's collaboration with Amazon Web Services (AWS). This partnership is designed to accelerate drug discovery and optimize manufacturing processes, leveraging AWS's advanced AI and cloud computing infrastructure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGenomic Sequencing:\u003c\/strong\u003e Partnerships with firms like Illumina provide access to advanced genomic sequencing technologies, vital for identifying drug targets.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAI for Drug Discovery:\u003c\/strong\u003e Collaborations with tech giants such as Amazon Web Services (AWS) are being established to integrate AI into early-stage drug research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAI for Manufacturing:\u003c\/strong\u003e The AWS partnership also aims to apply AI to improve the efficiency and effectiveness of Amgen's drug manufacturing operations.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmgen strategically partners with patient advocacy organizations to gain crucial insights into patient needs. This collaboration directly influences Amgen's product development pipeline and informs their market strategies. These partnerships are vital for developing targeted educational programs and raising overall disease awareness.\u003c\/p\u003e\n\u003cp\u003eIn 2024 alone, Amgen's dedicated partnerships with these organizations were instrumental in facilitating educational programs that reached an impressive audience of over 500,000 patients. This demonstrates a tangible commitment to patient support and education.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Insights:\u003c\/strong\u003e Collaborations provide direct feedback on patient experiences, unmet needs, and treatment preferences.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Access:\u003c\/strong\u003e Advocacy groups can help navigate regulatory pathways and improve patient access to therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDisease Awareness:\u003c\/strong\u003e Joint initiatives enhance public understanding of specific diseases and the importance of early diagnosis and treatment.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Support Programs:\u003c\/strong\u003e Partnerships facilitate the development and dissemination of resources that support patients throughout their treatment journey.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships: Catalysts for Biopharma Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen's key partnerships are crucial for its innovation and market reach, encompassing academic institutions for early research, tech companies for AI integration, and patient groups for market insights.  These collaborations are vital for accessing cutting-edge science, scaling production, and ensuring patient-centric development, all while navigating the complex biopharmaceutical landscape.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership Type\u003c\/th\u003e\n\u003cth\u003eKey Partners (Examples)\u003c\/th\u003e\n\u003cth\u003eStrategic Importance\u003c\/th\u003e\n\u003cth\u003e2024\/Recent Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic \u0026amp; Research\u003c\/td\u003e\n\u003ctd\u003eMIT, Harvard Medical School, Stanford University\u003c\/td\u003e\n\u003ctd\u003eEarly-stage research, scientific breakthroughs, access to specialized knowledge\u003c\/td\u003e\n\u003ctd\u003e$5.1 billion R\u0026amp;D investment in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing \u0026amp; Acquisition\u003c\/td\u003e\n\u003ctd\u003eHorizon Therapeutics plc (acquired Oct 2023)\u003c\/td\u003e\n\u003ctd\u003eBroaden therapeutic pipeline, rapid access to innovative products\u003c\/td\u003e\n\u003ctd\u003e$27.8 billion acquisition of Horizon Therapeutics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapeutic Collaborations\u003c\/td\u003e\n\u003ctd\u003eBeiGene, Ltd. (partnership established 2023)\u003c\/td\u003e\n\u003ctd\u003eDevelop and commercialize oncology treatments in Asia\u003c\/td\u003e\n\u003ctd\u003eFocus on China and other Asian markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eContract Manufacturing Organizations (CMOs)\u003c\/td\u003e\n\u003ctd\u003eScale production, manage capacity, ensure therapy availability\u003c\/td\u003e\n\u003ctd\u003e$1 billion NC manufacturing facility expansion began 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTechnology \u0026amp; AI\u003c\/td\u003e\n\u003ctd\u003eIllumina, Amazon Web Services (AWS)\u003c\/td\u003e\n\u003ctd\u003eGenomic sequencing, AI for drug discovery and manufacturing\u003c\/td\u003e\n\u003ctd\u003eAWS collaboration announced Nov 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient Advocacy\u003c\/td\u003e\n\u003ctd\u003eVarious patient advocacy organizations\u003c\/td\u003e\n\u003ctd\u003ePatient insights, market access, disease awareness, patient support\u003c\/td\u003e\n\u003ctd\u003eReached over 500,000 patients through educational programs in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAmgen's business model focuses on leveraging cutting-edge biotechnology to discover, develop, manufacture, and market innovative human therapeutics, primarily targeting serious illnesses with unmet medical needs.\u003c\/p\u003e\n\u003cp\u003eThis model emphasizes a strong R\u0026amp;D pipeline, strategic partnerships, and a robust manufacturing and distribution network to deliver life-changing medicines to patients globally.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eAmgen's Business Model Canvas offers a clear, structured approach to identifying and addressing the complex challenges inherent in biopharmaceutical innovation, acting as a pain point reliver by simplifying strategic planning.\u003c\/p\u003e\n\u003cp\u003eIt provides a visual framework to pinpoint and resolve operational hurdles, thereby streamlining the path from scientific discovery to patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development (R\u0026amp;D)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen's core activity revolves around robust Research and Development (R\u0026amp;D) to create groundbreaking human therapeutics. They concentrate on critical areas with significant unmet medical needs, including oncology, cardiovascular health, inflammatory conditions, and rare diseases.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Amgen significantly boosted its R\u0026amp;D commitment, investing a record $6.0 billion. This represents a substantial 25% increase compared to the previous year, underscoring their dedication to innovation.\u003c\/p\u003e\n\u003cp\u003eThis substantial investment fuels the advancement of Amgen's extensive pipeline, which features numerous potential medicines aiming to be first-in-class or best-in-class treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trials and Regulatory Approvals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmgen's core operations heavily rely on conducting extensive clinical trials. These trials are crucial for validating the safety and effectiveness of their innovative drug candidates across various disease areas. This rigorous testing phase is a fundamental step before any new therapy can be considered for public use.\u003c\/p\u003e\n\u003cp\u003eGaining regulatory approval is a critical milestone, with bodies like the U.S. Food and Drug Administration (FDA) playing a key role. Amgen successfully navigated this process in 2024, securing important approvals for therapies such as BLINCYTO and IMDELLTRA, underscoring their ability to bring new treatments to patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen's key activities heavily involve the intricate manufacturing of its biologic therapies, a process demanding specialized facilities and highly controlled procedures.  This complexity is crucial for ensuring the efficacy and safety of their innovative treatments.\u003c\/p\u003e\n\u003cp\u003eEfficient supply chain management is another cornerstone, guaranteeing that Amgen's vital medicines reach patients worldwide reliably and on time. This global distribution network is essential for patient access to life-changing therapies.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Amgen continued to leverage significant manufacturing capacity at its key sites, including its substantial operations in Puerto Rico. These facilities are central to producing a large volume of its commercial drug supply, underscoring their importance in Amgen's operational strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization and Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmgen's commercialization and sales efforts focus on effectively bringing its innovative medicines to patients and healthcare providers globally. This encompasses robust marketing strategies, a dedicated sales force, and efficient global distribution networks. The company's commitment to this crucial stage is evident in its substantial investments in its commercial infrastructure.\u003c\/p\u003e\n\u003cp\u003eIn 2024, Amgen reported impressive global sales figures, reaching approximately $29.6 billion. This financial performance underscores the success of their commercialization strategy in reaching a wide patient population and generating significant revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarketing and Promotion:\u003c\/strong\u003e Amgen employs targeted marketing campaigns to educate healthcare professionals and patients about the benefits and appropriate use of its therapies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSales Force:\u003c\/strong\u003e A large, specialized sales force is deployed to engage with physicians, hospitals, and payers, ensuring product access and adoption.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Distribution:\u003c\/strong\u003e The company manages a complex supply chain to ensure its medicines are available to patients in numerous countries worldwide.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024 Sales Performance:\u003c\/strong\u003e Amgen's global sales reached approximately $29.6 billion in 2024, reflecting strong market penetration and demand for its product portfolio.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiosimilar Development and Launch\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmgen's biosimilar segment is a critical component of its strategy to broaden patient access and compete in evolving markets. The company is actively engaged in the development and commercialization of these more affordable alternatives to biologic medicines.\u003c\/p\u003e\n\u003cp\u003eThe company has strategically launched biosimilars such as Wezlana, Pavblu, and Bekemvy, with launches occurring in 2024 and extending into 2025. These launches are designed to capture market share and provide cost-effective treatment options.\u003c\/p\u003e\n\u003cp\u003eAmgen has set ambitious growth targets for its biosimilar business, projecting that sales from this segment will more than double by 2030. This demonstrates a significant commitment to expanding its presence in the biosimilar space.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiosimilar Portfolio Expansion:\u003c\/strong\u003e Amgen is actively developing and launching biosimilars, including Wezlana, Pavblu, and Bekemvy, with key launches in 2024 and 2025.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Competitiveness:\u003c\/strong\u003e These biosimilar offerings are crucial for Amgen to maintain competitiveness and offer more affordable treatment options to a wider patient population.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFuture Growth Projections:\u003c\/strong\u003e The company anticipates more than doubling its biosimilar sales by the year 2030, highlighting a strong focus on this segment's growth potential.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnovating Medicines: From Lab to Global Patient Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmgen's key activities encompass the entire lifecycle of innovative drug development and delivery. This includes extensive research and development, rigorous clinical trials, and securing regulatory approvals, as evidenced by their 2024 investment of $6.0 billion in R\u0026amp;D and approvals for BLINCYTO and IMDELLTRA. Furthermore, they manage complex manufacturing processes for biologics and ensure efficient global supply chain management to deliver these vital medicines to patients. Their commercialization efforts, supported by a dedicated sales force and marketing strategies, drove global sales to approximately $29.6 billion in 2024. Amgen is also strategically expanding its biosimilar portfolio, aiming to more than double biosimilar sales by 2030 with launches like Wezlana and Pavblu in 2024-2025.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eKey Activity\u003c\/th\u003e\n\u003cth\u003eDescription\u003c\/th\u003e\n\u003cth\u003e2024 Highlight\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n\u003ctd\u003eCreating groundbreaking human therapeutics for unmet medical needs.\u003c\/td\u003e\n\u003ctd\u003e$6.0 billion investment, a 25% increase.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Trials\u003c\/td\u003e\n\u003ctd\u003eValidating safety and effectiveness of drug candidates.\u003c\/td\u003e\n\u003ctd\u003eCrucial for advancing pipeline.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Approval\u003c\/td\u003e\n\u003ctd\u003eSecuring necessary approvals from bodies like the FDA.\u003c\/td\u003e\n\u003ctd\u003eApprovals for BLINCYTO and IMDELLTRA.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eComplex production of biologic therapies.\u003c\/td\u003e\n\u003ctd\u003eLeveraging significant capacity at key sites.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply Chain Management\u003c\/td\u003e\n\u003ctd\u003eEnsuring reliable and timely global distribution.\u003c\/td\u003e\n\u003ctd\u003eEssential for patient access.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization \u0026amp; Sales\u003c\/td\u003e\n\u003ctd\u003eBringing medicines to patients and healthcare providers.\u003c\/td\u003e\n\u003ctd\u003eGlobal sales reached ~$29.6 billion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar Development\u003c\/td\u003e\n\u003ctd\u003eDeveloping and launching affordable alternatives.\u003c\/td\u003e\n\u003ctd\u003eLaunched Wezlana, Pavblu, Bekemvy; aiming to double sales by 2030.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe Amgen Business Model Canvas preview you are viewing is the exact document you will receive upon purchase. This means you're seeing a direct representation of the final, comprehensive business model that will be delivered to you, ensuring no discrepancies or altered content. Once your order is complete, you will gain full access to this same, professionally structured document, ready for your immediate use and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55611178942841,"sku":"amgen-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amgen-business-model-canvas.png?v=1754752345","url":"https:\/\/growthsharematrix.com\/products\/amgen-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}